Following a Federal Government announcement in December 2015, four new drugs for hepatitis C will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2016. The new drugs are: Sofosbuvir, Ledipasvir, Daclatasvir, Ribavirin, and can be used to treat patients with specific genotypes of hepatitis C (genotypes 1, 2 and 3). GPs have a major role to play in the diagnosis, assessment and treatment of patients with mild hepatitis C and referral of patients with more serious, advanced cases of the disease. GPs will be able to obtain Autho...